{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975666",
  "id": "02975666",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250801",
  "time": "0730",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdwwc2rtwrgv.pdf",
  "summary": "- **R&D Pipeline**: Targets addressable markets worth over **US$8 billion**, with 8 patented products and 24 off-patent injectables in development.  \n- **FY26 Guidance**: Operating profit expected at **$20.0\u201324.0 million**.  \n- **FY27 Revenue Target**: **$300 million**, supported by market expansion investments.  \n- **Key Commercialization Programs**: Maxigesic\u00ae, Crystaderm\u00ae, Micolette\u00ae, Kiwisoothe\u00ae, and capsaicin cream for osteoarthritis/neuropathic pain.  \n\n*No capital markets actions (e.g., raising, halt) or material liquidity/capital structure updates identified.*",
  "usage": {
    "prompt_tokens": 1072,
    "completion_tokens": 137,
    "total_tokens": 1209,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T21:32:53.487542"
}